BIOVERSYS N (BIOV) — research page
CH · ch-cm-kg/SIX/BIOV · as of 2026-11-06
Identity and listing
BIOVERSYS N is listed on SIX under ticker BIOV, ISIN CH0210362643, LEI 894500UFIGC75NPZEZ68. Its security type is Corporate, and it is a Zefix-registered corporation in Switzerland. Segment and sector are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | BIOVERSYS N | source · 2026-11-06 |
| exchange | SIX | source · 2026-11-06 |
| ticker | BIOV | source · 2026-11-06 |
| ISIN | CH0210362643 | source · 2026-11-06 |
| LEI | 894500UFIGC75NPZEZ68 | source · 2026-11-09 |
| security type | Corporate | source · 2026-11-06 |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | Switzerland (Zefix-registered corporation) | source · 2026-11-06 |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 19 filings in the twelve months to 2026-11-06, across 14 filing days. The median gap between filing days is 13 days. The latest filing is dated 2026-10-29, eight days before the record date, and is of type ad hoc. The exchange median is 29.5 days across 607 issuers, and the exchange median latency is 14 days. Sector medians are not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 19 | 13 | 8 |
| exchange median: SIX (607 issuers) | 0 | 29.5 | 14 |
| date | type | category | filing |
|---|---|---|---|
| 2026-10-29 | ad_hoc | ad-hoc | BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100 | Ad-hoc - EQS News |
| 2026-10-29 | ad_hoc | ad-hoc | BioVersys announces first patient first visit in Phase 2b RIV ... |
| 2026-10-22 | corporate_news | corporate | BioVersys’ BV100 Phase 2 exploratory data selected for rapid fire and poster presentations at IDWeek 2026 | Corporate - EQS News |
| 2026-10-22 | corporate_news | corporate | BioVersys' BV100 Phase 2 exploratory data selected for ... |
| 2026-09-09 | corporate_news | BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028 |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record. The record carries the annual report link only, which is a source link and not a read. The auditor's location is not on the record, and auditor changes are not on the record.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, because this register has no lifecycle type map yet. The halt flag is listed, not halted.
Orderability
The outcome is ACM-200 for private clients, professional clients and institutional clients. The outcome is determinable for all three categories. The rule version is acm-68000/ch/finsa-product-duties/r1, and the chapter is as of 2026-11-04.
| client category | outcome |
|---|---|
| Privatkundinnen und -kunden | ACM-200 |
| institutionelle Kunden | ACM-200 |
| professionelle Kunden | ACM-200 |
rule acm-68000/ch/finsa-product-duties/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The research-house coverage field has not been read.
Open research
The open research field has not been read.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No sealed issuer years are on the record, the market's earliest sealed date is not on the record, and the live record start date is not on the record.
Sources
7 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.six-group.com/en/products-services/the-swiss-stock-exchange/market-data/shares/share-explorer.html (identity.exchange)
- 10.2
- https://www.zefix.ch/en/search/entity/list?name=BIOVERSYS (identity.jurisdiction)
- 10.3
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.4
- https://mcp.ch-cm-kg.ai/events/SIX/BIOV (the disclosure lines)
- 10.5
- https://www.ser-ag.com/sheldon/official_notices/v2/find.json ; https://www.bxswiss.com/suspensions (the halt flag)
- 10.6
- https://mcp.ch-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.7
- https://mcp.ch-cm-kg.ai/record/SIX/BIOV (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"CH0210362643"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:542970c0e01cbf1c.